Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.91
-5.0%		$1.97
$1.17
▼
$2.71
$224.55M0.3431,696 shs190,011 shs
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$1.65
$1.65
$1.37
▼
$2.25
$138.32M0.28N/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.03
+3.2%		$1.29
$0.97
▼
$2.73
$338.57M2.26.91 million shs3.91 million shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
+8.06%+3.08%-11.06%+11.05%-3.37%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00%0.00%0.00%0.00%-17.50%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.01%-6.54%-27.27%-19.35%-14.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.91
-5.0%		$1.97
$1.17
▼
$2.71
$224.55M0.3431,696 shs190,011 shs
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$1.65
$1.65
$1.37
▼
$2.25
$138.32M0.28N/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.03
+3.2%		$1.29
$0.97
▼
$2.73
$338.57M2.26.91 million shs3.91 million shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
+8.06%+3.08%-11.06%+11.05%-3.37%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00%0.00%0.00%0.00%-17.50%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.01%-6.54%-27.27%-19.35%-14.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.67
Moderate Buy$6.67249.04% Upside
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00
N/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
2.60
Moderate Buy$9.50822.33% Upside

Current Analyst Ratings Breakdown

Latest OCGN, IPHYF, and IPHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/12/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $9.00
8/11/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/11/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy ➝ Outperform
8/11/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00
8/10/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$5.00 ➝ $7.00
6/26/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/23/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$10.19M20.94N/AN/A($0.26) per share-7.35
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$10.19M13.57N/AN/A($0.29) per share-5.69
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.41M79.20N/AN/A($0.04) per share-25.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)
Innate Pharma SA stock logo
IPHYF
Innate Pharma
-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$67.85M-$0.26N/AN/AN/AN/A-127,987.80%-115.95%11/4/2026 (Estimated)

Latest OCGN, IPHYF, and IPHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/17/2026N/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
-$0.2912N/AN/AN/A$6.28 millionN/A
9/16/2026Q2 2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$0.2946-$0.12+$0.1746-$0.12$6.35 million$3.23 million
8/6/2026Q2 2026
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.0533-$0.07-$0.0167-$0.07$0.89 million$1.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/A
1.27
1.27
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
1.27
1.27
Ocugen, Inc. stock logo
OCGN
Ocugen
4.17
0.80
0.80

Institutional Ownership

CompanyInstitutional Ownership
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.16%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
31.89%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
31.89%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
163111.72 million76.09 millionNot Optionable
Innate Pharma SA stock logo
IPHYF
Innate Pharma
17983.83 million57.10 millionNot Optionable
Ocugen, Inc. stock logo
OCGN
Ocugen
116339.11 million325.72 millionOptionable

Recent News About These Companies

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
September 15 at 12:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-ocugen-targets-three-gene-therapy-bla-filings-as-retinal-pipeline-advances-2026-09-15/
What is HC Wainwright's Forecast for Ocugen FY2028 Earnings?
September 14 at 1:42 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31021687
What is HC Wainwright's Estimate for Ocugen FY2028 Earnings?
September 14 at 1:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-ocugen-fy2028-earnings-2026-09-14/
What is HC Wainwright's Forecast for Ocugen FY2029 Earnings?
September 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31019786
Ocugen (NASDAQ:OCGN) CEO Shankar Musunuri Sells 468,727 Shares of Stock
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-ocugen-nasdaq-ocgn-ceo-shankar-musunuri-sells-468727-shares-of-stock-2026-09-11/
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945553-ocugen-q3-data-catalyst-in-stargardt-disease-feels-critical
What is HC Wainwright's Estimate for Ocugen FY2029 Earnings?
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-ocugen-fy2029-earnings-2026-09-11/
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945149-ocugen-my-hold-rating-continued-on-ocu410st-advancement-and-upcoming-catalysts
What's Happening With Ocugen Stock Thursday?
September 10, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61713486/whats-happening-with-ocugen-stock-thursday?utm_source=snapi
Ocugen slips after interim trial data for Stargardt disease candidate
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4641296-ocugen-slips-stargardt-disease-trial-data
Ocugen, Inc. (OCGN) Stock Price, News, Quote & History - Yahoo Finance
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/OCGN/latest-news/
Ocugen, Inc. (NASDAQ:OCGN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ocugen-inc-nasdaq-ocgn-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-09-08/
Bank of America Corp DE Grows Stock Position in Ocugen, Inc. $OCGN
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-grows-stock-position-in-ocugen-inc-ocgn-2026-09-03/
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
September 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2983803/ocgn-advances-gene-therapy-ocu410-in-phase-iii-for-geographic-atrophy?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2983803
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ocgn-advances-gene-therapy-ocu410-145200805.html
Ocugen Eases on Tests
September 1, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23969/Ocugen-Eases-on-Tests
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation
September 1, 2026  |  quiverquant.comQ
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3353979/0/en/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-modifier-gene-therapy-for-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration.html
27,002,933 Shares in Ocugen, Inc. $OCGN Acquired by BlackRock Inc.
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-27002933-shares-in-ocugen-inc-ocgn-acquired-by-blackrock-inc-2026-09-01/
Ocugen's September Reckoning: A Fully Funded Pipeline Faces Its First Real Efficacy Test
September 1, 2026  |  ad-hoc-news.deA
Ocugen, Inc. (OCGN) Stock Earnings Call Transcripts - Yahoo Finance
August 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/OCGN/earnings-calls/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$1.91 -0.10 (-4.98%)
Closing price 04:00 PM Eastern
Extended Trading
$1.93 +0.02 (+0.99%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Innate Pharma stock logo

Innate Pharma OTCMKTS:IPHYF

$1.65 0.00 (0.00%)
As of 09/16/2026

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.03 +0.03 (+3.17%)
Closing price 04:00 PM Eastern
Extended Trading
$1.03 0.00 (-0.10%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas